Eli Lilly and Co (NYSE:LLY) announced it is acquiring SiteOne Therapeutics, a private biotech firm developing small-molecule inhibitors of sodium channels to treat pain and other neuronal hyperexci...

Eli Lilly And Co LLY on Tuesday agreed to acquire SiteOne Therapeutics, Inc., a private biotechnology company developing small-molecule inhibitors of sodium channels to treat pain and other neurona...

Eli Lilly's (LLY -0.12%) share price soared during the first Trump administration. That momentum continued with Joe Biden in the White House.

The authorization in Australia is for adult patients who are Apolipoprotein E- ε 4 heterozygotes or non-carriers INDIANAPOLIS , May 21, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announ...

Eli Lilly (LLY 3.47%) has a strong pipeline of new medicines that could increase the stock price.

Eli Lilly (LLY 3.47%) is gaining market share in a lucrative market that could be a catalyst for a stock price increase.

Eli Lilly and Company (NYSE:LLY ) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - SVP, IR Conference Call Participa...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Participants achieved an average weight loss of 20.2% with Zepbound vs. 13.7% with Wegovy In key secondary endpoints, Zepbound was superior to Wegovy across all weight reduction targets and waist c...

President Donald Trump's second term in office has been challenging for investors, at least so far. Trump imposed sweeping tariffs on imports from most countries worldwide.

Any time is a great time to buy stocks -- if you pick the right stocks. That's true even in May, a month where some investors have traditionally opted to take a break from the stock market for the ...

LLY's valuation remains highly attractive post-market overreaction, with the FY2025 bottom-line impact merely attributed to one-time acquired IPR&D expenses from ongoing M&A activities. Despite the...

Eli Lilly and Company (NYSE:LLY ) Q1 2025 Results Conference Call May 1, 2025 10:00 AM ET Company Participants Mike Czapar - Senior Vice President of Investor Relations Dave Ricks - Chair and CEO L...

Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat estimates.

Eli Lilly and Co (NYSE:LLY) shares fell as much as 7.7% at the open on Thursday after the drugmaker cut its 2025 profit forecast, overshadowing booming sales of its blockbuster weight-loss drugs. T...